TRx-237-005 Clinical Study

This clinical trial will assess the safety and efficacy of LMTX™ in up to 700 patients diagnosed with mild Alzheimer’s Disease.  The main measures of efficacy to be used in the study are:

  1. The change in study subjects’ performance at the beginning and the end of the study in two commonly used clinical assessments:
    • The Alzheimer’s Disease Assessment Scale – Cognitive Subscale, known as ADAS-cog11
    • The Modified Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change, known as ADCS-CGIC
  2. The reduction in decline in glucose uptake in the temporal lobe as measured by FDG/PET imaging
  3. The safety and tolerability of LMTX™ given for up to 18 months

The treatment period will be 18 months and the study, which will be placebo-controlled, is planned to take place at approximately 100 clinical sites primarily in the US and EU and is expected to last for 3 years.


Global Alzheimer's study site locator

If you are a patient, caregiver, or family member of someone with Alzheimer's and interested in learning more, click the link below to find a clinical research study site near you. (Please note that this information is managed by a third-party, MediciGlobal.) 


FTD Global Study Locator

Alzheimer's Global Study Locator

Genting Invests with TauRx for Stake in Alzheimer's Market Leadership